膀胱癌靶向药物的新载体:金属纳米粒子  

A new carrier of targeted drugs for bladder cancer:metal nanoparticles

作　　者：余潇 许盛涵 陈波 王强 YU Xiao;XU Shenghan;CHEN Bo;WANG Qiang(Department of Urology,The Affiliated Hospital of Guizhou Medical University,Guiyang 550004;Department of Urology,Liupanshui People s Hospital,Liupanshui 553000;Department of Urology,The Affiliated Hospital of Changchun University of Chinese Medicine,Changchun 130021,China)

机构地区：[1]贵州医科大学附属医院泌尿外科,贵州贵阳550004 [2]六盘水市人民医院泌尿外科,贵州六盘水553000 [3]长春中医药大学附属医院泌尿外科,吉林长春130021

出　　处：《现代泌尿外科杂志》2025年第2期174-179,181,共7页Journal of Modern Urology

摘　　要：膀胱癌(BCa)目前临床上的治疗以手术为主,并辅以术后化疗、免疫治疗等。然而由于缺乏特异性、靶向性等原因,治疗效果不理想。近年研究发现使用金、银等制备的金属纳米粒子(MNPs)作为膀胱灌注药物或作为药物载体时不仅能够精确靶向到BCa细胞,具有较高的稳定性和药物释放率,还能降低化疗药物的不良反应发生率。本文结合国内外研究综述了近年MNPs在BCa治疗中的研究进展,简要总结金纳米粒子、银纳米粒子、铜纳米粒子等类型的MNPs在BCa治疗中的应用,并对膀胱灌注结合纳米药物的发展趋势做出展望。The current clinical treatment of bladder cancer(BCa)is mainly surgical treatment,supplemented by postoperative chemotherapy and immunotherapy.However,due to the lack of specificity,targeting and other reasons,the therapeutic effect is not satisfactory.In recent years,it has been found that metal nanoparticles(MNPs)prepared by gold,silver,and so on,as bladder infusion drugs or drug carriers,can not only accurately target BCa cells,but also have high stability and drug release rate,thereby reducing the side-effects of chemotherapy drugs.Based on domestic and foreign studies,this paper reviews the progress of MNPs in the treatment of BCa,including gold,silver,copper and other MNPs,and prospects the trend of bladder perfusion combined with nanomedical drugs.

关 键 词：膀胱癌 靶向治疗 纳米粒子 金属纳米粒子 光动力治疗 免疫治疗 

分 类 号：R737.14[医药卫生—肿瘤]